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Abstract
Aim Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor developed for the treatment of heart fail-
ure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade
of the angiotensin receptor AT1. The many peptides metabolized by NEP suggest multifaceted potential consequences of its
inhibition. We sought to evaluate the short-term changes in serum endorphin (EP) values and their relation with patients’
physical functioning after initiation of sacubitril/valsartan treatment.
Methods and results A total of 105 patients with heart failure with reduced ejection fraction, who were candidates for
sacubitril/valsartan treatment, were included in this prospective, observational, multicentre, and international study. In a first
visit, and in agreement with current guidelines, treatment with angiotensin-converting enzyme inhibitors or angiotensin recep-
tor blocker was replaced by sacubitril/valsartan because of clinical indication by the responsible physician. By protocol, pa-
tients were reevaluated at 30 days after the start of sacubitril/valsartan. Serum levels of α- (α-EP), γ-Endorphin (γ-EP), and
soluble NEP (sNEP) were measured using enzyme-linked immunoassays. New York Heart Association (NYHA) functional class
was used as an indicator of patient’s functional status. Baseline median levels of circulating α-EP, γ-EP, and sNEP were 582
(160–772), 101 (37–287), and 222 pg/mL (124–820), respectively. There was not a significant increase in α-EP nor γ-EP serum
values after sacubitril/valsartan treatment (P value = 0.194 and 0.102, respectively). There were no significant differences in
sNEP values between 30 days and baseline (P value = 0.103). Medians (IQR) of Δα-EP, Δγ-EP, and ΔsNEP between 30 days
and baseline were 9.3 (34  44), 3.0 (46.0  18.9), and 0 units (16.4  157.0), respectively. In a pre–post
sacubitril/valsartan treatment comparison, there was a significant improvement in NYHA class, with 36 (34.3%) patients
experiencing improvement by at least one NYHA class category. Δα-EP and ΔsNEP showed to be significantly associated with
NYHA class after 30 days of treatment (P = 0.014 and P < 0.001, respectively). Δα-EP was linear and significantly associated
with NYHA class improvement after 30 days of sacubitril/valsartan treatment.
Conclusions These preliminary data suggest that beyond the haemodynamic benefits achieved with sacubitril/valsartan, the
altered cleavage of endorphin peptides by NEP inhibition may participate in patients’ symptoms improvement.
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Introduction
Sacubitril/valsartan is a first-in-class angiotensin receptor
neprilysin inhibitor developed for the treatment of heart fail-
ure (HF) with reduced ejection fraction (HFrEF). The
PARADIGM-HF trial, which tested sacubitril/valsartan for
treating HFrEF, showed that it was superior to enalapril in re-
ducing the risk of cardiovascular death and HF hospitalization,
as well as improving quality of life of surviving HFrEF pa-
tients.1,2 The benefits of sacubitril/valsartan are achieved
via two mechanisms: (i) the inhibition of neprilysin (NEP)
causes an increase in the activity of its substrates, such as na-
triuretic peptides, and (ii) the specific blockade of the angio-
tensin receptor AT1 instead of the inhibition of the
angiotensin-converting enzyme.3
Neprilysin is an abundant enzyme that can also be found in
its circulating soluble form, which has emerged as a new bio-
marker with promising implications for prognosis and therapy
in patients with HF.4–6 Its ubiquity allows it to participate in
the degradation path of multiple substrates, suggesting many
multifaceted potential consequences of its inhibition beyond
the natriuretic peptide system.7 Neuropeptides, including
endorphins (EPs), are also recognized substrates that NEP is
capable of degrading. α-Endorphin (α-EP) and γ-Endorphin
(γ-EP), well-known endogenous opioid peptides, have
morphinomimetic behaviour, affect several physiologic activ-
ities, and are potential antipsychotic and analgesic drugs.8
EPs are also capable of producing feelings of welfare and tol-
erance to pain.9,10
In the present work, we aimed to explore the dynamics of
serum EPs values in patients with HFrEF upon treatment with
sacubitril/valsartan and its relation to the improvement in
functional class assessed by New York Heart Association
(NYHA) class.
Methods
Study design and participants
A prospective, observational, multicentre, international study
was conducted between 1 November 2016 and 1 December
2017. Patients were eligible if they had stable HF with left
ventricular ejection fraction ≤40% and were under treatment
with angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker (Figure 1).
In a first visit, and in agreement with current guide-
lines,11,12 treatment with angiotensin-converting enzyme in-
hibitor or angiotensin receptor blocker was replaced by
sacubitril/valsartan because of clinical indication by the re-
sponsible physician. Doses of sacubitril/valsartan treatment
were individualized. By protocol, patients were reevaluated
at 30 days after the start of sacubitril/valsartan, and no
other therapeutic modifications were performed between
both visits. Demographic information, medical history, vital
signs, 12-leads electrocardiogram, standard laboratory data,
and pharmacological treatments were routinely assessed at
visits. A trained cardiologist assessed the NYHA association
class in the study visits. The estimated glomerular filtration
rate (eGFR) was estimated by the Modification of Diet in
Renal Disease Study equation, based on creatinine and
other characteristics of the patients. Institutional commit-
tees of each participating centre approved the study proto-
col, local ethics committees approved the study, and all
patients provided written informed consent prior to enrol-
ment. This study was conducted in accordance with the
Declaration of Helsinki. Patients with presence of
extracardiac disease with an estimated life expectancy of
less than 1 year, treated with narcotic analgesics, with mod-
erate to severe alcoholism, severe renal (eGFR < 30
mL/min/1.73 m2) or severe hepatic insufficiency (Child-Pugh
C classification), hyperkalaemia (>5.4 mmol/L), systolic
blood pressure < 100 mmHg, prior history of angioedema,
pregnant women, or participating in randomized clinical
trial, were excluded.
Measurement of serum endorphins levels
Blood samples were collected and serum was obtained by
centrifugation for 10 min at 3000 rpm and stored at
80°C. All samples were obtained between 09:00 am and
12:00 pm using the same protocol at the first visit and at
30 days.
α-EP was measured by Human α-Endorphin ELISA kit
(BlueGene Biotech; Shanghai, China; Code No. E01A3095;
Lot No. 20161219). Serum aliquots were diluted 1:2 in PBS
(pH 7.0–7.2). This assay has high sensitivity and excellent
specificity for detecting α-EP, and the manufacturer observed
no significant cross-reactivity or interference between α-EP
and analogues. The range of the assay is between 0 and
2500 pg/mL. The sensitivity in this assay is 1.0 pg/mL.
γ-EP was analysed by a competitive binding enzyme-linked
immunosorbent assay technology, Human γ-Endorphin ELISA
kit (Abbexa Ltd.; Cambridge Science Park, Cambridge, UK;
Code No. abx258229; Lot No. L201701A884). Assay’s range
is between 12.35 and 1000 pg/mL, and assay’s sensitivity is
5.47 pg/mL.
Measurement of sNEP
Soluble neprilysin was measured by a sandwich immunoassay
human neprilysin/CD10 ELISA kit (Aviscera Bioscience; Santa
Clara, CA; Code No. SK00724-01; Lot No. 20113187). Serum
aliquots were diluted one quarter in dilution buffer provided
by the manufacturer before incubation. Standard range and
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sensitivity are between 62.5–8000 and 30 pg/mL, respec-
tively. Physicians in charge of clinical assessment were
blinded to endorphins and sNEP levels.
Statistical analysis
Continuous variables were expressed as mean (±standard de-
viation) or median (interquartile range) as appropriate. Dis-
crete variables were expressed as percentages. The primary
outcome was the association between absolute changes in
plasma Δα and Δγ-endorphins (visit posttreatment  visit
pretreatment) with the NYHA class at 30 days (NYHA30-d
class). Secondary outcome included the association between
ΔsNEP (visit posttreatment  visit pretreatment) and
NYHA30-d class. The independent association among these
markers and NYHA30-d class was tested with analysis of co-
variance. NYHAbaseline class was included as a covariate in all
models. Other covariates were selected by means of multi-
variable fractional polynomial method, which combines back-
ward elimination with the selection of a fractional polynomial
function. This ensures the right match between the functional
form of continuous covariates and the outcome. A two-sided
P value of <0.05 was set as alpha for all analyses. All analyses
were performed using Stata 14.1.
Results
Baseline characteristics of HF patients treated with
sacubitril/valsartan are shown in Table 1. A total of 115 pa-
tients admitted in six sites in four countries (Spain, Italy, the
Netherlands, and United States) were enrolled. However,
we excluded 10 patients because they did not attend the
follow-up visits, or they admitted they did not adhere to
treatment. The median (IQR) age was 68 years (60–75), and
81 (77.1%) were male. The most frequent aetiology was
ischaemic heart disease (62.9%). Baseline medians of left ven-
tricular ejection fraction, NT-proBNP, and eGFR were 30%
(25–35), 925 ng/L (374–1700), and 64 mL/min/1.73 m2 (50–
82), respectively. The starting dose of sacubitril/valsartan
was 24/26 mg in 67 (63.8%) and 49/51 mg in 38 (36.2%) pa-
tients according to their clinical status.
Baseline median levels of circulating α-EP, γ-EP, and sNEP
were 582 (160–772), 101 (37–287), and 222 pg/mL (124–
820), respectively. There was not a significant increase of
α-EP nor γ-EP serum values after sacubitril/valsartan treat-
ment (P value = 0.194 and 0.102, respectively). There were
no significant differences in sNEP values between 30 days
and baseline (P value = 0.103). Medians (IQR) of Δα-EP, Δγ-
EP, and ΔsNEP between 30 days and baseline were 9.3
(34  44), 3.0 (46.0  18.9), and 0 units (16.4 
157.0), respectively (Table 1). Baseline NYHA functional class
is shown in Table 1. After 30 days treatment with
sacubitril/valsartan, a significant improvement in NYHA class
was found (Figure 2), with 36 (34.3%) patients experiencing
improvement by at least one NYHA class category. Before
sacubitril/valsartan treatment 8.6% of the patients were in
NYHA class I, while after the treatment the percentage of pa-
tients in NYHA class I was 32.4%. A multivariable analysis re-
vealed that NYHAbaseline class (Figure 3A), NT-proBNPbaseline
(Figure 3B), and eGFRbaseline (Figure 3C) were significant pre-
dictors of NYHA30-d class.
After forcing the three markers in the statistical model,
Δα-EP and ΔsNEP showed to be significantly associated
with NYHA class after 30 days of treatment (NYHA30-d class)
(P = 0.014 and P < 0.001, respectively). For Δα-EP, the
association was linear and negative (Figure 4A), where higher
Δα-EP values are indicative of lower NYHA30-d class. For
Δγ-EP, the association was not significant (Figure 4B). On
the other hand, ΔsNEP was positive and linearly associated
with higher NYHA30-d class (Figure 4C). In a sensitivity analy-
sis, the sacubitril/valsartan dose [(24/26)/(49/51)] was not
significant as predictor of NYHA30-d class, either as main
Figure 1 Patients flow diagram. ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blockers; ARNI, angiotensin receptor-
neprilysin inhibitor; HF, heart failure; LVEF, left ventricular ejection fraction.
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effect or as interacting with any of the markers (P value for
interactions for α-EP, γ-EP, and sNEP were 0.201, 0.808, and
0.233, respectively).
Discussion
In this contemporary cohort of patients with HFrEF, we found
an important association between Δα-EP and the early clinical
improvement after the start of sacubitril/valsartan. These
findings suggest that the altered cleavage of endorphin pep-
tides by NEP inhibition may participate in patients’ symptoms
improvement beyond the haemodynamic benefits achieved
with sacubitril/valsartan.
Heart failure is a chronic and progressive disease with
multiple hospital readmissions and worse prognosis. Symp-
toms of HF worsen patients’ quality of life substantially.
Thus, changes in one NYHA functional class category lead
to positive improvements in patient’s quality of life.13,14
Sacubitril/valsartan has proven to be a superior alternative
to angiotensin-converting enzyme inhibitor/angiotensin re-
ceptor blocker to treat HF, reducing the risk of death and
improving the condition of patients with HErEF.1,2,15
However, because of the large variety of substrates de-
graded by NEP, its pharmacological inhibition could lead to
a significant increase in its substrates deriving in unknown
effects.
Endogenous opioid peptides play an important role in the
management of pain and several physiological activities.16,17
They are known to be released with states of pleasure includ-
ing emotions brought upon by laughter, love, sex, and sports.
They are also involved in the development of cardiovascular
diseases such as hypertension and congestive HF, although
the mechanisms of action are not completely known.18,19 En-
dogenous opioid peptides may modulate cardiac function at
the hormonal level via coupling to mu opiate receptors,
which have impact in the heart’s performance and the vascu-
lature.20 Endorphins such as α-EP and γ-EP act as functionally
antagonistic neuropeptides in the brain, and their balanced
expression is very important for behavioural homeostasis.21
Its implication in diverse physiological activities determines
its importance to maintain a correct balance between them.
α-EP and γ-EP are both originated from the same precur-
sor22,23; the proteolytic activity cleaves β-EP into γ-EP and
convert it into α-EP.24 However, our results show that an in-
crease in α-EP was associated with an early clinical improve-
ment as determined by NYHA functional class. In spite that
α-EP and γ-EP are equivalent substrates for NEP,25 they seem
to evolve differently. The baseline values of α-EP were higher
than the basal values of γ-EP (582 vs. 101 pg/mL). This differ-
ence may be one of the reasons why there is an association
between NYHA class and α-EP and not with γ-EP. Serum
values of β-EP are well known in congestive26 and acute27
HF, but α-EP and γ-EP pathways are little studied in HF
patients.
Opioid peptides are susceptible to rapid enzymatic degra-
dation,28 and it is known that a lot of peptidases are involved
in their degradation, such as aminopeptidases, angiotensin-
converting enzyme, insulin-degrading enzyme, and dipeptidyl
peptidases, among others.29–31 Previous studies reported a
significant decrease in NHYA class after sacubitril/valsartan
treatment,31 and our data provide preliminary evidence of
the association between Δα-EP and the early clinical improve-
ment after sacubitril/valsartan treatment.
We did not find significant differences between baseline
and posttreatment α-EP levels in the whole sample. However,
Table 1 Baseline characteristics
Age (years) 66.7 ± 11.4
Men, n (%) 81 (77.1)
Aetiology, n (%)
CM ischaemic 66 (62.9)
CM hypertensive 4 (3.8)
CM dilated 35 (33.3)





Hypertension, n (%) 72 (68.6)
Dyslipidaemia, n (%) 72 (68.6)
Prior admission for acute heart failure, n (%) 54 (51.4)
Left ventricular ejection fraction (%) 30 (25–35) (25–35)
Heart rate (bpm) 65 (60–73)
Systolic blood pressure (mmHg) 115 (107–130)
Diastolic blood pressure (mmHg) 70 (62–78)
Urea (mg/dL) 45 (32–64))
Creatinine, mg/dL (IQR) 1.15 (0.95–1.38)
Sodium, mmol/L (IQR) 139 (137–141)
Haemoglobin, g/dl (IQR) 13.8 (12.4–14.8)
NT-proBNP, ng/L (IQR) 925 (374–1700)
eGFR, m/min/m2 (IQR) 64 (50–82)
α-EP, pg/mL (IQR) 582 (160–772)
γ-EP, pg/mL (IQR) 101 (37–287)
sNEP, pg/mL (IQR) 222 (124–820)
Δα-EP, units (IQR) 9.3 (34–44)
Δγ-EP, units (IQR) 3 (46–18.9)
ΔsNEP, units (IQR) 0 (16.4–157)
Treatments
Furosemide, n (%) 67 (63.8)
Torasemide, n (%) 15 (14.3)
Antialdosteronic, n (%) 91 (86.7)
Beta blockers, n (%) 101 (96.2)
Digoxin, n (%) 13 (12.4)
Statin, n (%) 71 (67.6)
Acetylsalicylic acid, n (%) 55 (52.4)
Nitrates, n (%) 15 (14.3)
Anticoagulants, n (%) 55 (52.4)
Initial daily dose Sac/Val 24/26 mg, n (%) 67 (63.8)
Initial daily dose Sac/Val 49/51 mg, n (%) 38 (36.2)
Values are expressed as mean ± SE or median (IQR).
CM, cardiomyopathy; EP, endorphin; eGFR, glomerular filtration
rate; NEP, neprilysin; NT-proBNP, N-terminal pro-brain natriuretic
peptides; NYHA, New York Heart Association; sNEP, soluble
neprilysin.
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Figure 2 NYHA class changes after sacubitril/valsartan initiation. NYHA, New York Hear Association.
Figure 3 NYHAbaseline class (A), NT-proBNPbaseline (B), and eGFRbaseline (C) were significantly predictors of the outcome. (A) Analysis adjusted by baseline
values of eGFR-MDRD method, and NT-proBNP, and α-endorphin, -Log--endorphin, and -sNEP. (B) Analysis adjusted by baseline values of NYHA class
and eGFR-MDRD method, and α-endorphin, -Log--endorphin, and -sNEP. (C) Analysis adjusted by baseline values of NYHA class, and NT-proBNP, and α-
endorphin, -Log--endorphin, and -sNEP. eGFR, estimated glomerular filtration index; NT-proBNP, N-terminal pro-brain natriuretic peptides; NYHA, New
York Heart Association; sNEP, soluble neprilysin; , 30-day minus baseline.
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we found a significant relationship between Δα-EP and NYHA
improvement. These findings suggest a heterogeneous and
idiosyncratic endorphins response to sacubitril/valsartan that
may partially explain the short-term clinical improvement
found in some patients.31–35 The absence of increased α-EP
and γ-EP after treatment with sacubitril/valsartan in all pa-
tients may be due to the existence of these degradation path-
ways, because of the importance of maintaining its
equilibrium for behavioural homeostasis.
This study has several limitations. The NYHA is based on
the subjective assessment made by the physician and a
more objective determination of the patients’ functional
status may be of interest. However, we should point out
that NYHA evaluation was blinded to clinicians. In addition,
because of the importance of the balance between α-EP
and γ-EP, the homeostatic mechanisms for this maintenance
could be the reason for not finding significant increases of
these substrates after the treatment with sacubitril/
valsartan; however, to corroborate this theory, further stud-
ies are necessary.
In conclusion, from an HF standpoint, endorphins and their
effects and interactions are yet partially understood and
studied. It is likely that endorphin elevation after NEP
inhibition may have autocrine, paracrine, or endocrine func-
tions; however, the duration and effects of endorphin eleva-
tion with sacubitril/valsartan is unclear. Our data suggest that
beyond the haemodynamic benefits achieved with
sacubitril/valsartan, the altered cleavage of endorphin pep-
tides by NEP inhibition may participate in patients’ symptoms
improvement.
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